Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

BioArctic, Audiocast, Q1'25

By Inderes5/21/2025, 7:30 AM
BioArctic

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Gunilla Osswald
00:01 - 18:05

Thank you so much. Good morning and welcome to BioArctic's presentation for the first quarter of 2025. BioArctic has now entered a new era, an era of profitable growth, which is signified by an extraordinarily strong first quarter and a lot of activities throughout the different parts of the business. I will talk more about that in today's presentation. And we take the next slide, please. I'm the CEO of BioArctic, and I will share today's presentation with our CFO, Anders Martin-Löf. Next slide, please. BioArctic is listed on Nasdaq Stockholm under the large-cap category. And this is our disclaimer. Next slide please. This enables even further activities across the business as we develop new and better treatments for patients with an increasing number of severe brain disorders. Let's look over some of the highlights this year. First of all, Leqembi is now approved in all major markets, including the US, Japan, China, and Europe. We see continued growth across markets, and more and more patients are getting access. We are very excited about our advancements in therapeutic development. The FDA recently approved the first blood test, which is used to diagnose Alzheimer's disease. So that means that even more patients will be able to be treated with Leqembi. I continue to be very excited about our brain transporter technology. The significant deal with Bristol Myers Squibb for our beta antibodies for Alzheimer's disease, including BAN 2401, which is utilizing our BrainTransporter technology, has now come into effect since February. And this agreement also opens up further opportunities for partnerships utilizing our BrainTransporter technology. It's also great to see the progress of the phase two. A study started late last year and is progressing really well. And according to plan, all patients have already completed dosing in the low dose part of the study, and we have expanded the study to also include Multiple System Atrophy (MSA) patients. Now, the quarter showed a record high profit due to several one-time events, including the upfront from Bristol Myers Squibb and milestone payments from Eisai, as well as continuous royalties on Leqembi based on these achievements. BioArctic has now entered the new era, which I call the 'BioArctic Growth Era,' and this is based on continuous and growing royalties, quarter on quarter, which provides us with stable revenues. And so we are no longer dependent on irregular milestones. BioArctic will achieve even more stable finances, and we expect to be profitable from this year onwards. Our BrainTransporter platform is validated with strong partnering interest, and it could potentially lead to several partnerships in the future. Our alpha-synuclein portfolio with exidavnemab and BT 2238 is also receiving a lot of interest among external partners. Next slide please. We are among the world leaders as innovators in these two areas. The first one is highly selective antibodies targeting aggregated forms of misfolded proteins. In Alzheimer's disease, Parkinson's disease, and ALS. The other area is our BrainTransporter technology, which helps biological treatments to penetrate the brain more effectively through the blood-brain barrier. And that results in a higher concentration of the treatment in the brain, close to the target. This means that it has the potential for an even better effect, a better safety profile, and lower doses, which makes it more convenient for patients. Our business model focuses on innovation in new treatments for neurodegenerative disorders, but we are also now a platform company with the BrainTransporter technology. Next slide please. The European Commission finally granted the market authorization for Leqembi in Europe. 15th of April this year. And this enables potential access to Leqembi in an additional 30 countries. It's indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease. We call those together early AD, and it is for patients who are APOE ε4 non-carriers or heterozygotes with confirmed amyloid pathology. So homozygous, which is about 10 to 15% of the population. They are excluded in Europe. The next step now in Europe will be to work on the controlled access program and post-authorization safety study and educational material for the introduction into the market and then local price and reimbursement discussions in each country. In total, Leqembi is now approved in 44 countries, and we are awaiting decisions in 12 additional countries. The European regulatory approval may serve as a reference for regulatory authorities in other countries where submissions are filed, in order to make the Leqembi administration even more convenient for patients as they are progressing different lifecycle management activities. The first one is the I.V. Maintenance dosing less frequently, and then it will be possible to give it every fourth week. And that has now been approved in the US. This means that after 18 months of dosing, patients could consider transitioning to dosing every four weeks instead. This supports long-term treatment, and it is important to continue the treatment to keep clearing the toxic species of amyloid. Also after that, the plaques are cleared and this is a clear benefit for Leqembi, as Eisai is also preparing for a broader submission of IV maintenance across markets. Another benefit for Leqembi is the subcutaneous auto injector, which makes the treatment even more convenient for patients. The FDA has accepted the filing for maintenance dosing with the PDUFA date of August 31st this year, so end of August. Eisai is also preparing for a supplementary BLA submission to the FDA for the subcutaneous auto injector for induction treatment. After the approval of the maintenance treatment. Next slide please. I think it was very reassuring to hear that real-world use confirms FDA prescribing recommendations with similar rates of side effects as in the Clarity AD Study. Data from the UK and the EU indicate that the population, excluding ApoE homozygotes, which I said is about 10 to 15% of the population. Data from that population were also presented, confirming that the effects of Leqembi were similar to the overall population in the Clarity study, and with a lower risk of adverse events. We are now looking forward to upcoming congresses, and the next one is AAIC in July in Canada, where I will present data from the Clarity AD open label extension study supporting early treatment and maintenance dosing. And now, we expect full-year data to be presented, along with more real-world evidence on the commercial side. As we progress in the commercialization of Leqembi across markets, adjustments are made for each market depending on the time point for market entry. The first phase I call 'initial approval,' and that's now where the EU and Asia are, areas where Leqembi has just recently been approved. Then, as marketing continues, they enter the demand creation phase. And this is similar to China's current state, which was launched last year. And then the third phase is the demand expansion phase. And here we see Japan having had the most successful launch. And now the US is also entering into the demand expansion phase in the EU. ASI aims to start launch later this year. As for most launches, the first countries tend to be Germany and Austria. At BioArctic, we are preparing for a Nordic launch together with Eisai, pending local reimbursement discussions, and the launch is estimated to start in the first half of next year. Next slide please. The first one is more convenient dosing, allowing for less frequent intravenous (I.V.) administrations. Dosing is now approved in the US. And the next step is a subcutaneous auto-injector. And that will make it even more convenient for the patients. The first BLA has been submitted for maintenance dosing. After the approval that we're hoping for at the end of August. Then, there is a plan to submit a supplementary BLA for the subcutaneous auto-injector for the induction phase. The subcutaneous auto injector will make the treatment much more convenient for the patients and for caregivers. So it's more feasible to administer this at home with fewer requirements and lower costs for administration compared to I.V. Infusions. It's very exciting. This could also shorten queues and free up time for specialists to focus on eligible patients. The third aspect is to broaden the indication to even earlier stages of Alzheimer's disease. And now we talk about pre-symptomatic individuals. So even before symptoms. The ongoing AHEAD 345 study will evaluate the effect of starting lecanemab treatment very early. I think this is a great opportunity, especially based on all the data that has been presented at Congresses on early patients, alluding towards even better effect when you start treatment early in the disease. Next slide please. The license agreement with Bristol Myers Squibb is a key event for biotech. It's a global license for our beta antibody programs. This partnership was effective from the 20th of February this year. I think Bristol Myers Squibb is a great partner for our beta program with patients in focus. We are now preparing for Bristol Myers Squibb (BMS) to take over the projects and drive them towards delivery to patients. This is our largest agreement which has been signed so far and one of the largest globally for such an early project. It includes 100 million USD upfront and another 1.25 billion USD in milestones, plus tiered low double-digit royalties on global sales. Importantly, BioArctic retains all other rights to the brain transporter technology outside of the beta field, and we have several interested partners and good discussions ongoing at BioArctic. We also continue to develop the BrainTransporter technology further, and we are working on broadening it into other modalities like enzymes and antisense oligos. Next slide please. And it's a potential disease-modifying treatment for several different neurodegenerative synucleinopathies. There are no existing disease-modifying treatments, and there is a huge medical need, with opportunities to help patients with Parkinson's disease, Lewy body dementia, Parkinson's disease with dementia, and multiple system atrophy. We have very strong preclinical data showing a reduction of the toxic forms of α-synuclein, delaying disease progression, and increasing lifespan in very tough Parkinson's disease mice. The two phase one studies performed showed an excellent PK profile and were well tolerated, supporting progression into phase two. Last week, the patent for X was granted in Europe, and it had previously also been granted in the US and in Japan. And we have a long patent life up to 2046, including extensions. Next slide please. The low dose part in patients with Parkinson's disease has been fully recruited and dosed, and we are now preparing for a safety readout. This summer we're also very excited about that. We now will include MSA patients in this trial. And the approval has been granted in both countries, Spain and Poland. We're also pleased that the FDA has granted orphan drug designation for MSA. I think it offers opportunities to support several different neuronal synuclein hypotheses, such as Parkinson's disease. Lewy body dementia and multiple system atrophy. Next slide please. There are no disease-modifying treatments available, and there is a huge unmet medical need. It's a tough disease. It's fatal and rapidly progressing, with a lifespan from diagnosis of about 6 to 8 years. Patients suffer from motor symptoms and autonomic dysfunction. It is an orphan drug indication, and we have received orphan drug designation in the US, for example, which is beneficial for continued drug development. Now, new biomarkers are being developed both for diagnosis and to follow disease progression. And this is also improving the possibilities for drug development. MSA alone as an indication is of blockbuster level, and the molecule also has opportunities with other, even larger indications. Next slide please. And today in the presentation, I have highlighted the Leqembi, exidavnemab beta programs, and our BrainTransporter platform. And I'm pleased to say that BioArctic's innovation and research with high quality is also being recognized externally. Next slide please. And by that, I hand over to Andrea Martin for the financial summary.

Anders Martin-Löf
18:05 - 27:42

Thank you. Starting with the Leqembi sales, the global Q1 sales were ¥14.7 billion. That's roughly $96 million. That's roughly an 11% increase from the fourth quarter last year, or a 380% increase for the first quarter of 2024. You see the royalty numbers in the graph to the left of the box, and they look a little bit unusual. The recorded royalty for the quarter was 96.96 million Swedish kronor. Uh, but that includes a currency effect from the Q4 royalty of 5.7 million Swedish. So the accrued royalty for Q1 was 101.7 million. So, we saw solid growth in the underlying royalties in line with the sales basically. If you then look at the different markets globally, I would really want to highlight Japan. That has been incredibly successful. There was a 9% increase from the fourth quarter last year, up to ¥4.4 billion, or $29 million. Uh, we also saw solid growth in the US, with a 4% increase up to $52 million. And it looks like we have stellar growth in China, going up 46% from the fourth quarter, but that's really chalk-based, so it's hard to draw many conclusions from that. But it's really reassuring to see good growth in all the markets overall. Their full-year forecast increased by roughly 4%, reaching ¥4.3 billion, or roughly $290 million in full-year sales in their fiscal year 2024. Looking forward a little bit, as Gunilla mentioned, the US market is now following Japan into the demand expansion phase as Eisai calls it. And what that really is about is trying to focus on leveraging the core data that emphasizes the benefit of early treatment for patients, especially those in the earlier stages of mild cognitive impairment. Almost all of them are treated in primary care, and the vast majority of them have not even been diagnosed. So, it's a big imperative to really focus on increasing engagement with primary care practitioners to encourage coordination with specialty care, so you can get more of those patients into treatment. So Eisai is now targeting roughly 2,000 primary care practitioners during the year, with the sales force and learning from Japan. They're also now starting direct-to-consumer campaigns to increase brand awareness and disease awareness, to really create more of a pull from the patients. And of course, this is facilitated by the streamlining pathway that we also talked about. So I think we will see some effect of this increased focus on primary care for primary care practitioners in the US already this year, but I expect the full effect to be seen basically in 2026. So it will be very interesting to follow this going forward based on that. If we turn to the next slide. Eisai has updated a forecast for their fiscal year 2025, where they believe the sales will grow by 73% globally to ¥76.5 billion. Um, as you can see in the chart, they expect 53% growth in the US, but still 88% growth in Japan and then even higher growth in China and other markets. If this happened, it would correspond to roughly 510 million Swedish krona in royalties during the same time period. Uh, and over time, Eisai has issued a revenue simulation in March of roughly ¥250 to ¥280 billion in 2027. And if you look at the growth rates in the coming years that are necessary to reach that, they are basically expecting similar or even higher growth in the coming years. Um, one question we always get is how likely it is to reach this forecast. And we think it looks really good. They indicated during their quarterly update with analysts that already in April, the sales in Japan, for example, were ¥2 billion. Uh, so they're already at the level that would indicate an annual level of ¥24 billion. So if they keep growing in Japan, it looks possible to actually beat the forecast in Japan and hopefully it will have a similar situation in the other countries. So, we remain very confident that they can reach this global forecast. Turning then to our financials on the next slide. On the left-hand side, you can see that our revenues have increased from 30 million last year to 1,290 million Swedish krona this year, which is a fairly large increase. This is, of course, driven by the upfront payment from BMS of $100 million. But we also see the milestone payments from Eisai of €10 million, which was the sales milestone. The EU approval milestone of €20 million was not recorded in the first quarter, but it will be recorded in the second quarter. This is also supported by the royalty revenues. I have already mentioned that there were 96 million, and we also had some promotional revenue, totaling 3 million. But over time, as we have said in the past, these recurring revenues will become more and more important. But in this quarter, they are really dwarfed by the enormous upfront payments and milestone payments. Looking a little bit at the costs in the middle, the operating expenses have increased to 203 million in the quarter. The big increase is mainly explained by an increase in other operating costs, which was 72 million. And this is basically a currency effect on the upfront payment from BMS. And out of that, R&D makes up 65%. So the vast majority of our costs are spent on R&D and really accelerating our portfolio. And the costs are expected. The underlying costs, I should say, are expected to increase during 2025 as our product portfolio progresses, and we will also increase our commercial expenses. Uh, when we intensify the preparations for the launch of the company in the Nordics. I previously said that I expect the cost to increase by roughly 50 to 80% this year. Uh, I should probably revise the lower limit there to roughly 60% because we will have this. Uh, I did not anticipate this currency effect. So if I were to guess today, I would say that our costs will increase by roughly 60 to 80% this year compared to last year. Uh, then on the right hand side, you see our operating profit, which was, uh, almost 1.1 billion Swedish in the first quarter. Uh, I'm sad to say, but the remaining quarters of the year will be slightly less profitable than that. So, we expect the full year profit to be roughly in line with the first quarter, but as I already mentioned, we expect to remain profitable for the coming year. So it's really a big shift for us becoming more of a profitable company going forward. On the last slide that I would show, on the next slide you see the net result. It's roughly 55 million Swedish below the operating profit. And that is explained by a financial net of -9 million. And we have also recorded a tax expense of 44 million in the quarter. The cash flow is much weaker than the result. And that is then also explained by the upfront payment from BMS. So, we didn't see the cash effect of that. But we did receive the funds for the €10 million sales milestone. So at the end of the first quarter, our cash balance was roughly 800 million Swedish. But already a couple of weeks after the closing of the quarter, we received all of a billion SEK. So following us in the remainder of the year, you will see that our financial position will strengthen in the coming quarters from a cash perspective. So all in all, we are in really good shape and are really looking forward to investing more and working hard to accelerate our portfolio and focus on the launch of Leqembi in the Nordics. With that, I turn back to Gunilla for some final remarks.

Gunilla Osswald
27:42 - 30:21

Thank you so much, Anders. So we're coming to the final part of the presentation with upcoming news flow and some closing remarks. Next slide, please. But before that, I want to welcome you all to our first Capital Markets Day, which is planned for the 2nd of June. It will be live in Stockholm and it will also be live-streamed. We are looking forward to giving our shareholders an in-depth look at our business and our ongoing research. It will be presented by some of my colleagues in the management team, and there will also be an opportunity to listen to a distinguished scientist and clinician who has treated several hundred patients with Leqembi in the US. If you are interested, then please register at. The last day of registration is the 28th of May. Next slide please. Um, for Leqembi, for example, in the EU. And we're looking forward to more regulatory responses. The next important Congress is AIC, where we look forward to several presentations on Leqembi. During the third quarter. And then, um. That's actually what I see in the third quarter. That's, of course, the regulatory response on, uh, subcutaneous autoinjector as maintenance treatment in the US and a subsequent filing for induction treatment with a subcutaneous autoinjector. And we also look forward, then, to the Exidavnemab safety review and progression into the high dose part in Parkinson's disease and also in MSA in the EXIST Phase 2a study. Next slide please. The company is now approved in all major markets. And more and more patients are getting access to treatment. We concluded our first license agreement utilizing our BrainTransporter technology and it continues to generate great external interest. The indications have now expanded, and we are preparing for several different opportunities for phase two. The profits so far this year are great, and they will make BioArctic highly profitable for this year. Next slide please. And we're happy to take some questions.

Anders Martin-Löf
30:25 - 30:43

You wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Victor Sundberg from Nordea. Please go ahead.

Gunilla Osswald
30:46 - 30:47

Yes.

Anders Martin-Löf
30:47 - 31:19

Hi. Hi. Thanks for taking my questions. I have three questions and I can take them one by one. So now with Leqembi approved in Europe. How do you see the Nordic launch of Leqembi? Are any costs increasing ahead of the launch, and also for your internal planning, when is it expected that the Dental and Pharmaceutical Benefits Agency in Sweden and other neighboring countries will be done with its health economic analysis of Leqembi and subsidize the drug? I can start there. Thanks.

Gunilla Osswald
31:24 - 31:26

Do you want to take that on this?

Anders Martin-Löf
31:26 - 31:58

Um, so, if we start on the cost side. So yes, we will see some increasing costs. Not, uh, not by a really large number, but, yes, the costs will increase during the year. Um, I should have a look at what they were, and maybe I will have a look at what they were in the quarter and give you some guidance on how much they will grow during the remainder of the year while providing a response on what happens on the reimbursement side, for example.

Gunilla Osswald
31:58 - 32:52

Yeah. So I can also say, I mean, we have, as you know, started to build our commercial organization a couple of years ago with strategic positions. But now, since we got the approval in Europe, we are also hiring a small number of customer-facing resources. But it will be a fairly small organization because we are also, um, sharing the marketing and commercialization with Eisai. Um, and then Eisai is in the lead and they are driving the price and reimbursement discussions. And we are supporting, and it's really quite rewarding. And they are driving it. And I think that we can expect that the price and reimbursement discussions will continue this year. And, uh, hopefully we'll have a good outcome next year.

Anders Martin-Löf
32:53 - 33:06

Yeah. And the marketing and sales costs in the quarter were roughly 19 million. Um, I would estimate that they would increase by roughly ten to fifteen percent per quarter in the coming quarters.

Gunilla Osswald
33:09 - 33:35

Okay. Thank you. Uh, I noticed that Lundbeck's mascot trial in MSA will read out in 2028. Um, their Phase 3. Uh, if you continue running the program in MSA yourself. Um, is this an opportunity, uh, more for 2030 and beyond, or how do you see that program going forward? So yes, we will see some increasing costs.

Anders Martin-Löf
33:36 - 33:36

Yeah.

Gunilla Osswald
33:36 - 35:20

So first of all, we are really happy that we now can include MSA patients in the ongoing phase two study. And, uh, that will, um, we think have the same readout as for Parkinson's disease, which I think is a tremendous piece of work from our organization. Um, and for the sites and for the patients, then we are looking into different approaches going forward for MSA, for Parkinson's disease, for PD and DLB. And we are exploring different alternatives to advance some of the indications either independently or with a partner. So we are looking into several different opportunities, and there are opportunities to drive it very aggressively for MSA, for example, or a little bit more conservatively. So that's the kind of discussions that we are preparing for, going up to the board later on to have those conversations. So, and we're also looking at other important readouts, which are coming later this year, also in MSA by another competitor. So I think we're learning a lot from different competitors in this area. So sometimes it's good not to be first. Sometimes it's good to be first. Sometimes it's good to learn from others, as we have done in Lecanemab. And it can be. We have learned a lot from others and we are in the same situation right now, learning a lot. So there is no clear, easy answer to your question. So we are working on different approaches, but I think most likely it will be, um, not before 2030.

Anders Martin-Löf
35:22 - 35:51

Okay. Um, and also, um, yes. Um, going back again to this program, um, what kind of efficacy signals could we get from the phase two? I guess you won't be evaluating any scales in Parkinson's or MSA, but in terms of the biomarkers you're talking about, what could potentially give the most information about efficacy, or in your opinion, how should you maybe plan your future trials in Parkinson's and MSA. Thank you.

Gunilla Osswald
35:52 - 36:41

Very good question again, Victor. So I just want to manage expectations that the phase two study is really mainly a safety, tolerability and pharmacokinetic study to determine what dosage should be used in the next study. We are also casting a wide net of different biomarkers, more for exploratory purposes and to prepare for the next study where we really would expect to see a clinical effect. But we are looking into several blood-based biomarkers, we are also looking into digital biomarkers and so forth. So we will see if we get any signal, but it will be at most on the signal level. So the study is really focused on safety, tolerability, and pharmacokinetics, preparing for the next important study.

Anders Martin-Löf
36:44 - 36:49

Okay. Yeah. Thank you very much for giving me these answers. Really helpful. Thank you.

Gunilla Osswald
36:49 - 36:50

Thank you, Victor.

Anders Martin-Löf
36:55 - 36:59

The next question comes from Joseph Hedden from Securities. Please go ahead.

Gunilla Osswald
37:02 - 37:42

Good morning and thanks for taking my questions. Congrats on the strong quarter. Um, my question is about the expectations to be sustainably profitable. Um, I know this is something that you've reiterated since the full year results. Since then, we've had this revenue simulation, which was, um, modestly reduced from the previous projection. So, I'm just wondering, is there any expectation regarding that? Is there a milestone component of your expectation for 2026, or are you expecting to be profitable purely from the royalties you receive?

Anders Martin-Löf
37:43 - 38:06

So it will probably be a combination, with some royalties and some sales milestones going forward. So, we haven't really specified exactly if it's only royalties or only milestones, but if we get the expected combination of royalties and milestones, we expect to be profitable. I can't be more specific than that.

Gunilla Osswald
38:11 - 38:41

Okay. Thank you. Um, and then I was just wondering from the, uh, the EXIST trial of MSA, just to understand what we'll be getting. So, we have a safety review in Q3, and that's going to primarily involve PD patients. Um, so the top line results are expected in the first half of 2026. Is that going to be the Parkinson's disease cohort, or is that also going to include the MSA patients, or do they come at a later date because it started later for them?

Anders Martin-Löf
38:44 - 39:28

Thank you for that question, Joseph. So you're absolutely right that we are looking forward to the safety review of the low dose in Parkinson's disease patients around summer, and then both the Parkinson's disease and MSA patients can be treated simultaneously in two different cohorts during the autumn and going forward. And then we expect we'll see how quickly both of those indications can recruit. But there is a possibility, of course, that both of them can be ready because they will be done in parallel, for readout next year.

Gunilla Osswald
39:32 - 39:34

Okay, great. Thanks. Thanks.

Anders Martin-Löf
39:35 - 39:36

So we have a safety review in Q3, and that's going to primarily be PD patients.

Gunilla Osswald
39:40 - 39:45

The next question comes from Susanne van Hausen from Van Kempen. Please go ahead.

Anders Martin-Löf
39:48 - 40:07

Hello. Thanks for taking my question and congratulations on the strong quarter. This is on behalf of Suzanne Van Houten. Um, I was wondering, could you please elaborate on your intentions for further partnership or collaboration for the BrainTransporter platform?

Gunilla Osswald
40:10 - 40:11

Yeah.

Anders Martin-Löf
40:12 - 42:02

I wish I could tell you more, but I will not. I mean, I can just say that the BrainTransporter is progressing really well. We are driving the platform forward ourselves. We are also expanding it with enzymes and oligos. Uh, ASOs, um, internally as well. We are in discussions with external companies in order to see how they could potentially utilize our BrainTransporter technology. And that means that we would then take in another project, re-engineer that asset, and then hand it back to the company who would drive it forward. So that's the kind of business model that we're opening up for now. But I will not disclose any more details about ongoing discussions. But I think that we have really, I mean, opened up since the plan was all along, since November last year, to go out and talk about the BrainTransporter technology, show what we have done with our internal programs, add it into all our internal programs, and then open it up for possibilities for other companies to utilize our technology platform by us helping to re-engineer their assets. And that makes it a new chemical entity. That could be going forward. And I think the exciting thing here is that by doing this, we see that there is an opportunity for a better effect, a better safety profile, because you enter the brain in another way. And also, you can administer lower doses. That helps reduce the cost of goods, but also it's more convenient for patients. So I think this is very, very exciting. And it's great to see that we have a lot of interest from several external parties.

Gunilla Osswald
42:04 - 42:06

That is very, very helpful. Thank you very much.

Anders Martin-Löf
42:07 - 42:08

Thank you, Suzanne.

Gunilla Osswald
42:12 - 42:16

The next question comes from Rajan Sharma from Goldman Sachs. Please go ahead.

Anders Martin-Löf
42:19 - 42:43

Hello. Thanks for taking my question. So one on Leqembi in the Nordic regions. I just wanted to get a sense of your confidence that there's sufficient infusion capacity in the region. And I just wondered if you have any visibility on potential. Potential blood-based tests, both in the Nordic region and Europe more broadly. And then I had another one which I can follow up on.

Gunilla Osswald
42:44 - 45:31

Okay. Thank you. And, um, I think there is a clear interest from many different sites that they would like to initiate and start with the program. And so we really hope that all of this will be worked out in a good way with the price and reimbursement part. And then, uh, preparation for the Nordics. And then the, um, the blood-based, um, uh, biomarkers in, in the Nordics and in Europe. And then I think it's really, uh, good for the Nordics that Sweden is one of the areas that have been part of leading the whole development of blood-based biomarkers, both from the Gothenburg region and from the Skåne region. So there are really, really good opportunities, and they are utilizing it already on a smaller pilot scale, but it can be utilized step by step. So, but it's not yet fully approved in Europe, but it's being used on a smaller scale to start with. And you know, that you could start by way of screening, which means that if you then have a high level showing that you, with high likelihood, have amyloid deposits in the brain, then you know with high likelihood, if you have some clinical signs, that it's Alzheimer's disease. If you have very low levels, then you know that it's not Alzheimer's disease. If you are intermediate, that's when you really need to verify with amyloid PET or with CSF samples. So, um, I think what we really look forward to is when we can utilize the blood-based biomarkers also as confirmational, which has now happened in the US. And I think that it is also well on its way in Europe, but it's already being used to some extent. But, of course, when you can replace PET and CSF, that makes it much, much better for primary care and so forth. And broader use.

Anders Martin-Löf
45:31 - 45:32

Okay.

Gunilla Osswald
45:33 - 45:35

I hope that answered your question.

Anders Martin-Löf
45:36 - 45:54

It did. And then the follow-up was actually just a couple. So maybe slightly related to that, I'm sorry if you've addressed this on previous conference calls, but how feasible do you think it is to develop a formulation of the BrainTransporter?

Gunilla Osswald
45:56 - 46:18

I mean, that's definitely our ambition. So, uh, that's definitely in our plans that by utilizing our BrainTransporter, those assets could also utilize subcutaneous administration. That's definitely our ambition. And I think that's likely.

Anders Martin-Löf
46:21 - 46:23

Okay. Thank you.

Gunilla Osswald
46:27 - 46:28

Thank you.

Anders Martin-Löf
46:29 - 46:33

The next question comes from Alastair Campbell from RBC. Please go ahead.

Gunilla Osswald
46:35 - 47:28

Good morning everyone. Thanks so much for taking my questions. Um, I've got three questions, please. Just on that point, can you please remind me of the differentiation versus other molecules in the field? And you've touched on the specificity for the toxic form, but maybe just remind us how, um, it stacks up against some of the other competing antibodies. Um, then secondly, um, with amyloid beta antibodies, obviously ARIA emerged as kind of a hallmark safety signal from the data you've seen so far with, um, with alpha synuclein antibodies. Has anything emerged as kind of a hallmark safety signal, or is there anything specific you're going to be looking for that could be related to alpha synuclein depletion? And then maybe finally, um, just get a sense of your relative confidence in the mechanism. I mean, is there any reason to believe that MSA might lend itself more favorably versus Parkinson's disease, or is it broadly applicable across both? Thank you.

Anders Martin-Löf
47:30 - 50:49

Three excellent questions. Thank you, Alistair. So, for the first one, regarding differentiation, I would point to two different things. The first point is that it is more selective than the other options we are aware of. And the selectivity here, I think, is quite important because you have so much α-synuclein in the blood. So it's really important that you, um, target the aggregated forms, the toxic forms, while you spare the monomers, which have physiological significance. So, uh, I think that is an important part. And there we are definitely the most selective among those that we are aware of. The other aspect that also helps is that we also have a superior pharmacokinetic profile with a longer elimination half-life than the others. So we have a 30-day elimination half-life. This means that you get higher exposure, so you could then lower the dose a bit. So I think the combination of the high selectivity and the pharmacokinetic profile makes them stand out as a differentiated and very attractive asset. Then your second question was with regard to the safety of alpha-synuclein. And I'm really reassured by the data we have seen so far from all competitors that we are aware of, as it has shown quite good safety profiles so far. So I think that is also really helpful for us as we move forward, enhancing my expectations. Of course, then for the safety review that we have in front of us. And then your third question was about the mechanism of action, which I think is an excellent question. Um, thinking about which indication that could be the best indication for, um, going forward. And I think there are different pros and cons for several of the different indications. And that's why we have such interesting work in front of us to really see which indications we should start with and which ones could come later. There are opportunities both in MSA, which is a more aggressive disease variant than Parkinson's disease. But on the other hand, there is the possibility that it's an orphan drug indication. You can then do shorter studies and so forth, but it's a more aggressive disease. And then there is a scientific debate. If it targets, then, um, different parts in the cells and so forth with the alpha synuclein. Um, so uh, and then Parkinson's disease with motor symptoms or Lewy body dementia or Parkinson's disease. Dementia or going very early in Parkinson's disease. So we're looking into several different opportunities and seeing which would be the preferred approach going forward after this. So this phase 2a study opens up opportunities for several different other indications for the next step, which is phase 2b. I hope that answered your question, Alistair.

Gunilla Osswald
50:51 - 51:22

Yeah. That's great. If you don't mind, can I come back with just a follow up on that? Um, so if there's a lot of alpha-synuclein in the blood itself, does that potentially create issues around designing a BT, a BrainTransporter, a technology adaptation? I mean, does it run the risk of the product being sequestered in the blood if it binds too heavily to the blood form of alpha-synuclein, or could it even end up dragging alpha-synuclein into the brain as a result of that technology? Just wondering if that creates kind of quirks in terms of how the BT could work.

Anders Martin-Löf
51:22 - 52:33

Yeah, so I think, I mean, if you compare alpha synuclein with amyloid beta, alpha synuclein, there, we can have different mechanisms of action. We can reduce the spreading between cells, but we can also have an effect on the cells because alpha-synuclein also exists within the cells. So we need to enter the brain and then lower the spreading within the brain while also ideally penetrating the cells. And we have data showing that with our antibodies, we are also entering and can come into the cell and have the effect even there. So I think it is important to have a lower binding in the blood and then also especially to have it in the brain where you can do it. But I mean, there's a lot of ongoing work, and we are really putting a lot of effort into driving this forward, especially with our BT 2238 program, which continues to progress. Well.

Gunilla Osswald
52:36 - 52:37

Thank you.

Anders Martin-Löf
52:38 - 52:39

Thank you, Alistair.

Gunilla Osswald
52:43 - 52:47

The next question comes from Alistair from Carnegie. Please go ahead.

Anders Martin-Löf
52:50 - 54:10

Yes. Hi. Thanks for taking my question. Uh, questions? I have a few, uh, mainly on, uh, starting with Leqembi's future launch in Europe. So can you talk a bit. And I recognize that there are many different countries and healthcare systems, but can you talk about potential bottlenecks in the uptake in Europe compared to, for example, the US. Uh, relating to specific bottlenecks like PET diagnosis, infusion capacity, or MRI capacity, etc. Where do you see, is there a difference in which will be the most important bottlenecks in Europe for the uptake compared to the US, and then following up to that then related to that, maybe if you can talk a bit about how we should think about the uptake once you have price and reimbursement in the individual countries? Uh, other single-payer countries? Then I have a follow up. Thank you.

Gunilla Osswald
54:12 - 57:27

Thank you so much, Eric. Really good questions. So if I start, and I'm sure others will add to this, if you think about Europe, it consists of several different countries, each working with their own approach. So it's a quite complex market from that perspective. Um, and there are different healthcare systems, and in Sweden, we also consider the entire world divided into different regions. So, so I think you need to look at each country by itself. And then I would say that there are a lot of learnings that we can utilize from both the US and Japan, and to some extent China, with regard to what and how we can execute a really good launch. And we're committed to executing a highly successful launch. Um, and in the Nordics, in order to ensure that the right patients get access to Leqembi. So, for example, there are different bottlenecks, I think. Um, today you should then, I mean, confirm the amyloid pathology either through PET or CSF. Sweden is really good at doing CSF. It's not much of an issue. Um, there are some sites that can also do PET. Some other countries are less accustomed to using CSF. Um, and then it also depends on where you have your PET scans. So I also think that blood-based biomarkers have already started to be used. And we heard, I mean, a really strong advocate for the blood-based biomarkers from, uh, from Holland at the latest Congresses, and we know that it is being used in Sweden. So I think that we will see this being used more and more, at least as a first screening method in the system that I described. And I think this will then help the process to get the right patients more efficiently to memory clinics and specialist infusion capacities. I think there are a lot of learnings there from the US and Japan. And with the MRI capacity, I think there is a lot of work ongoing also with utilizing AI and other technologies to see how we can improve the approach with regard to MRI. So there is a lot of work to do in building up the infrastructure where we can utilize a lot. And I think, uh, China is quite interesting to look at because they have started with blood-based biomarkers and digital assessments. That was their approach. So it's a very different approach. Um, from the others. But I think the area to really focus on is Japan because they have executed a tremendous introduction and launch, which continues to perform really well. So, um, but it's also good to, to look at all learnings, um, from, from everywhere. So, um.

Anders Martin-Löf
57:30 - 58:06

There may be a follow-up to that regarding pricing in Europe. So considering President Trump's plan to leverage lower ex-US prices in negotiations with pharma companies and considering a relatively high price point in Japan, do you see a risk that Eisai might not launch in certain European countries if the price is too low to protect the US market?

Gunilla Osswald
58:07 - 58:15

So I will just refrain from commenting. I think it's Eisai who is the lead in the price and reimbursement discussions. And it's really their call.

Anders Martin-Löf
58:19 - 58:21

Okay. Sounds fair. Thank you.

Gunilla Osswald
58:22 - 58:23

Thank you, Eric.

Anders Martin-Löf
58:30 - 58:55

As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad. There are no more phone questions at this time. So I hand the conference back to the speakers for any written questions or closing comments.

Gunilla Osswald
58:57 - 59:01

Thank you. We have received some questions on the chat and.

Anders Martin-Löf
59:01 - 59:11

I will start with the question. If we plan to continue with the project alone, or if we are looking to make partnering agreements at some point.

Gunilla Osswald
59:12 - 60:12

So I think that, as you heard, I'm very excited about the project and the follow-on project. BT 2238 with the BrainTransporter for the α-synuclein. And here we are driving both programs ourselves, and we are open for discussions with partners. And we are having discussions with partners to strengthen our biotech capabilities. Where we are now is with our good financial position; we can drive the projects longer ourselves and increase the value more. Or we can partner if we get the right partner, just as it was with Bristol Myers Squibb. We did not have to partner that program, but we found the right partner and proceeded with the partnership then. So I see a very similar approach to exidavnemab. We believe strongly in this project. We will drive it forward and we have discussions. If we find the right partner, we will partner. Otherwise, we will continue ourselves. And I think we have a great asset with a lot of opportunities.

Anders Martin-Löf
60:14 - 60:22

Thank you. So the next question is how does the brain transporter platform compare to other similar platforms?

Gunilla Osswald
60:23 - 61:56

So I think the brain transporter technology and the blood-brain barrier technology, there are a lot of different companies working on this, and Roche is one of those who are in the lead and their technology, they call it Brain Shuttle. There are a lot of similarities with our brain transporter technology. We both utilize the transferrin receptor. There are some really important differences in how we bind to the brain transporter, which makes it, for example, possible to have a lower risk for some of the side effects. So I think that we have a very, very good approach in our own technology with the BrainTransporter, which I think can be utilized for many different projects in the future. So I think we have taken the best, and then they've made some tweaks, which makes it differentiated.

Anders Martin-Löf
61:58 - 62:10

Thank you. We are on to some questions on Leqembi. There's a question if we can discuss the patent strategy for Leqembi, such as possibilities for extensions and lifecycle management.

Gunilla Osswald
62:11 - 62:58

Yeah. So BioArctic, I mean, we work a lot with patent strategies and we have patent strategies, of course, for all our different targets. So in the Alzheimer’s part, we have several different patents, both with regard to the protofibrils and Leqembi. And then there are other opportunities that I cannot go into. But of course, we are very active in the patent strategy for Leqembi and for exidavnemab and for all our different assets for the BrainTransporter. Definitely. We have several different patents, and we're working on more patents. So this is one of the really important parts for an innovative company like BioArctic.

Anders Martin-Löf
62:59 - 63:08

We also have a question on the latest status of the research evaluation agreement with Eisai regarding BAN2401. If we can comment on that.

Gunilla Osswald
63:08 - 63:48

Yeah, that's also a very exciting collaboration with Eisai where we are utilizing our BrainTransporter technology. I'm not allowed to talk much about that program. So I can just say that it's an Alzheimer's program. Uh, this is a modifying treatment utilizing our BrainTransporter technology, and it's progressing really, really well. Um, so, uh, we are progressing towards acquiring more data, and then Eisai will review the program to see if they would be interested in further partnering.

Anders Martin-Löf
63:50 - 63:57

And one last question is when we can expect that BioArctic will start to pay dividends.

Gunilla Osswald
63:58 - 64:29

Maybe that's a question for me. Um, so we do have a dividend policy stating that we should start to pay dividends when we have proper financing that will not risk the development of our programs, etc.. Um, it's a little bit too early to tell exactly when that will happen, but if we are as profitable during this year and in the coming years, I think it's a fair expectation to expect that we will start to pay a dividend maybe next year or the year after that.

Anders Martin-Löf
64:31 - 64:36

Thank you. We have no further questions in the chat. So I hand back to you.

Gunilla Osswald
64:37 - 64:47

So I say thank you so much for your attention and for a lot of great questions. Um, so, and I wish you a great rest of the day. Thank you so much.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…